Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-302 in HER2 Positive Breast Cancer Patients
Enrollment in Phase 1 Study of MM-302 in HER2 Positive Breast Cancer Patients Initiated by Merrimack Pharmaceuticals
Cambridge, MA (PRWEB) August 08, 2011
Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase I clinical trial of MM-302, a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor.
The Phase 1 study in patients with advanced ErbB2 positive breast cancer is designed to evaluate the safety of MM-302 and identify the maximum tolerated dose. Four centers across the United States are currently expected to participate in this study. The first patient was enrolled at the Karmanos Cancer Institute at Wayne State University.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by the end of 2011.
Contact: Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043, kgallagher(at)merrimackpharma(dot)com
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424, betsy(at)raymondstevenson(dot)com
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/8/prweb8698020.htm